SEARCH

SEARCH BY CITATION

References

  • 1
    Meldrum BS. Glutamate as a neurotransmitter in the brain: review of physiology and pathology. J Nutr 2000;130:1007S15S.
  • 2
    During MJ, Spencer DD. Extracellular hippocampal glutamate and spontaneous seizure in the conscious human brain. Lancet 1993;341:160710.
  • 3
    Mayer ML, Armstrong N. Structure and function of glutamate receptor ion channels. Annu Rev Physiol 2004;66:16181.
  • 4
    Meldrum BS, Rogawski MA. Molecular targets for antiepileptic drug development. Neurotherapeutics 2007;4:1861.
  • 5
    Rogawski MA, Kurzman PS, Yamaguchi SI, Li H. Role of AMPA and GluR5 kainate receptors in the development and expression of amygdala kindling in the mouse. Neuropharmacology 2001;40:2835.
  • 6
    Lee WL, Hablitz JJ. Initiation of epileptiform activity by excitatory amino acid receptors in the disinhibited rat neocortex. J Neurophysiol 1991;65:8795.
  • 7
    Uchida K. Excitatory amino acid receptors appear to mediate paroxysmal depolarizing shifts in rat neocortical neurons in vitro. Brain Res 1992;577:1514.
  • 8
    Mccormick DA, Contreras D. On the cellular and network bases of epileptic seizures. Annu Rev Physiol 2001;63:81546.
  • 9
    French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004;62:125260.
  • 10
    Hashizume Y, Hanada T, Ogasawara A, Ueno M, Nishizawa Y. Anticonvulsant activity of perampanel, a selective AMPA receptor antagonist, in rodent models of epileptic seizure. Poster P02.113 presented at the 60th Annual Meeting of the American Acadamy of Neurology, April 15, Chicago, IL, USA, 2008.
  • 11
    Tokuhara N, Hatakeyama S, Amino H, Hanada T, Nishizawa Y. Pharmacological profile of perampanel: a novel, non-competitive selective AMPA receptor antagonist. Abstract presented at the American Academy of Neurology 2008 (abstract P02.112). Available at http://www.abstracts2view.com/aan2008chicago/view.php?nu=AAN08L_P02.112. 2008. Accessed 18 June 2010.
  • 12
    Templeton D. Pharmacokinetics of perampanel, a highly selective AMPA-type glutamate receptor antagonist. Poster 1.199 presented at the 63rd Annual meeting of the American Epilepsy Society, December 4–8, Boston, MA, USA, 2009.
  • 13
    Kennedy GM, Lhatoo SD. CNS adverse events associated with antiepileptic drugs. CNS Drugs 2008;22:73960.
  • 14
    Perucca P, Carter J, Vahle V, Gilliam FG. Adverse antiepileptic drug effects: toward a clinically and neurobiologically relevant taxonomy. Neurology 2009;72:12239.
  • 15
    Barcs G, Walker EB, Elger CE, et al. Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy. Epilepsia 2000;41:1597607.
  • 16
    Cereghino JJ, Biton V, Abou-khalil B, Dreifuss F, Gauer LJ, Leppik I. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 2000;55:23642.
  • 17
    Chappell AS, Sander JW, Brodie MJ, et al. A crossover, add-on trial of talampanel in patients with refractory partial seizures. Neurology 2002;58:16802.
  • 18
    Fuseau E, Templeton D, Hussein Z. Population pharmacokinetics and pharmacodynamics of perampanel in patients with refractory partial seizures. Epilepsia 2011, in press.